Lyra Therapeutics Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 <li /> Compa ...
PipelineReview.com4d
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...
MARKET REPORT: Builder Vistry plunges as cost issues hit profits
That includes a £25m profit hit in the current financial year, which will also be impacted by reduced expectations for sale ...
EuropaWire5d
Tezspire Shows Promise in Reducing Nasal Polyp Symptoms in Phase III Trial for Chronic Rhinosinusitis
6,7 Nasal polyps can block nasal passages and lead to breathing problems, difficulty in sense of smell, nasal discharge, ...
Battling Sinus Woes? Here’s How Seasonal Allergies Can Wreak Havoc and What You Can Do About It!
Expert says, that by recognising the connection between seasonal changes, allergies, and sinus health, individuals can take ...
AstraZeneca touts positive results from nasal polyp treatment study
AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis is a disorder characterised by ...
Le Lézard5d
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...